FibroBiologics (FBLG) to Release Earnings on Wednesday

FibroBiologics (NASDAQ:FBLG) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($1.3340) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 30, 2026 at 7:00 AM ET.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Stock Down 3.6%

Shares of FibroBiologics stock opened at $1.33 on Wednesday. The firm has a market cap of $4.67 million, a price-to-earnings ratio of -0.19 and a beta of 1.16. FibroBiologics has a twelve month low of $1.03 and a twelve month high of $22.60. The business has a 50-day moving average price of $3.82 and a 200-day moving average price of $5.39.

Insider Buying and Selling at FibroBiologics

In related news, CFO Jason Davis purchased 3,500 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was purchased at an average price of $8.20 per share, with a total value of $28,700.00. Following the completion of the purchase, the chief financial officer owned 3,500 shares of the company’s stock, valued at approximately $28,700. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 9,574 shares of company stock worth $72,886 over the last ninety days. Insiders own 13.00% of the company’s stock.

Institutional Trading of FibroBiologics

Institutional investors and hedge funds have recently modified their holdings of the stock. Landscape Capital Management L.L.C. bought a new stake in shares of FibroBiologics during the third quarter valued at approximately $191,000. Cerity Partners LLC raised its stake in shares of FibroBiologics by 37.2% during the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after acquiring an additional 34,702 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of FibroBiologics by 20.7% during the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after acquiring an additional 59,813 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of FibroBiologics during the second quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC raised its stake in shares of FibroBiologics by 287.3% during the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after acquiring an additional 171,800 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Maxim Group lowered FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. D. Boral Capital reiterated a “hold” rating on shares of FibroBiologics in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised shares of FibroBiologics to a “sell” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $74.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.